表 2. Clinical trials related to FMD in cancer therapy.

FMD在肿瘤治疗中的临床试验

Trial number	Therapeutic interventions	Cancer type	Number of participants	Status	Primary endpoints	Main study findings
NCT03700437	Chemo-immunotherapy + FMD	Non-small cell lung cancer	12	Completed	Feasibility and compliance	No results available
NCT03340935	Standard antitumour treatment + FMD	Different tumour types	101	Completed	G3/4 AE rate	Safety and feasibility of FMD; reduced glucose and growth factor levels after FMD; favorable reshaping of systemic and intratumor immunity after FMD
NCT04292041	Standard antitumor treatment + FMD	Prostate cancer	40	Completed	Body weight, abdominal circumference, and blood pressure	Weight loss, abdominal circumference reduction, and blood pressure reduction
NCT03595540	Active medical treatment + FMD	Different tumour types	90	Completed	Feasibility and safety	Safety and feasibility of FMD; reduced fat mass and plasma insulin, and IGF-1 and leptin levels after FMD
NCT02126449	Standard neoadjuvant chemotherapy + FMD	HER2-negative breast cancer	131	Completed	pCR rate	No pCR differences among groups; higher radiological response rates in FMD patients; higher Miller & Payne4/5 pathological responses in FMD patients; reduced DNA damage in T lymphocytes of FMD patients
NCT02710721	Chemotherapy + FMD	Prostate cancer	49	Completed	Quality of life changes	No results available
NCT03709147	Platinum salt + pemetrexed + pembrolizumab in association to metformin + FMD	Lung Adenocarcinoma	64	Recruiting	PFS	No results available
NCT05503108	Chemotherapy + FMD	HER2-negative Breast Cancer	240	Recruiting	Pathologic and radiologic response rate	No results available
NCT04248998	Preoperative chemotherapy + Metformin + FMD	Triple-negative Breast Cancer	30	Active, not recruiting	pCR rate	No results available
NCT05384444	Radical surgery + FMD	Colorectal Cancer	602	Recruitment has not started	DFS	No results available
NCT04027478	Chemotherapy + FMD	Different tumour types	39	Unknown status	Nausea grade	No results available
NCT03454282	Surgery + FMD	Breast cancer and melanoma	100	Completed	Absolute/relative changes in PBMCs	No results available